Baillie Gifford & Co
PACB icon

Baillie Gifford & Co’s Pacific Biosciences PACB Stock Holding History

Baillie Gifford & Co’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-561
Closed -$5K – 503
2022
Q1 		$5K Hold
561
– – ﹤0.01% 468
2021
Q4 		$11K Hold
561
– – ﹤0.01% 440
2021
Q3 		$14K Hold
561
– – ﹤0.01% 415
2021
Q2 		$20K Hold
561
– – ﹤0.01% 355
2021
Q1 		$19K Buy
561
+53
+10% +$1.85K ﹤0.01% 339
2020
Q4 		$13K Buy
+508
New +$8.63K ﹤0.01% 362

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Baillie Gifford & Co's PACB Position: Q2 2022 in Review

Baillie Gifford & Co sold out of Pacific Biosciences (PACB) in Q2 2022, closing a stake of 561 shares — an estimated $5K sold.

Baillie Gifford & Co first reported a position in PACB in Q4 2020 and held it in 6 quarters. The position peaked at $20K in Q2 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q2 2022.

  • Baillie Gifford & Co reported no remaining Pacific Biosciences position as of Q2 2022 after selling out during the quarter.
  • Baillie Gifford & Co sold 561 Pacific Biosciences shares in Q2 2022, an estimated $5K.
  • Baillie Gifford & Co first reported a position in Pacific Biosciences in Q4 2020 and held it in 6 quarters.
  • Baillie Gifford & Co's Pacific Biosciences position peaked at $20K in Q2 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2022.

Based on Baillie Gifford & Co's 13F filing for Q2 2022, filed 8 Aug 2022.